Literature DB >> 16930496

Saw palmetto and lower urinary tract symptoms: what is the latest evidence?

Andrew L Avins1, Stephen Bent.   

Abstract

The use of dietary supplements for treating a wide range of health conditions has grown rapidly in the United States. In the field of men's health, the most common dietary supplement used is an extract of the berry of the saw palmetto plant, with which men commonly self-medicate in order to treat lower urinary tract symptoms. Throughout the past two decades, substantial literature has emerged examining the biologic and clinical effects of saw palmetto extracts. Several lines of evidence suggest that saw palmetto may exert physiologic effects consistent with a beneficial clinical effect on the mechanisms of benign prostatic hyperplasia. Although most clinical studies tend to suggest a modest efficacy benefit of saw palmetto, more recent studies are less consistent and the precise clinical value of saw palmetto for treating lower urinary tract symptoms remains undefined. Overall, there appear to be few safety concerns with short-term use of this herbal medicine, although large-scale and longer-term safety studies have not been performed. Higher-quality studies are currently underway to better define the potential benefits and risks of plant-based extracts for treating symptoms related to benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930496     DOI: 10.1007/s11934-996-0004-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  38 in total

Review 1.  Phytotherapy in the treatment of benign prostatic hyperplasia: an update.

Authors:  F C Lowe; E Fagelman
Journal:  Urology       Date:  1999-04       Impact factor: 2.649

2.  Herbal Rx for prostate problems.

Authors: 
Journal:  Consum Rep       Date:  2000-09

3.  Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis.

Authors:  Frans Debruyne; Peter Boyle; Fernando Calais Da Silva; Jay G Gillenwater; Freddie C Hamdy; Paul Perrin; Pierre Teillac; Remigio Vela-Navarrete; Jean-Pierre Raynaud; Claude C Schulman
Journal:  Eur Urol       Date:  2004-06       Impact factor: 20.096

4.  Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.

Authors:  Fouad K Habib; Margaret Ross; Clement K H Ho; Valerie Lyons; Karen Chapman
Journal:  Int J Cancer       Date:  2005-03-20       Impact factor: 7.396

5.  Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.

Authors:  Steven H Yale; Ingrid Glurich
Journal:  J Altern Complement Med       Date:  2005-06       Impact factor: 2.579

6.  In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.

Authors:  Bill J Gurley; Stephanie F Gardner; Martha A Hubbard; D Keith Williams; W Brooks Gentry; Julie Carrier; Ikhlas A Khan; David J Edwards; Amit Shah
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

7.  Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia.

Authors:  Remigio Vela-Navarrete; Marta Escribano-Burgos; Antonio López Farré; Juan García-Cardoso; Felix Manzarbeitia; Carolina Carrasco
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

8.  Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial.

Authors:  K E Willetts; M S Clements; S Champion; S Ehsman; J A Eden
Journal:  BJU Int       Date:  2003-08       Impact factor: 5.588

9.  Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease.

Authors:  Andrew H Feifer; Neil E Fleshner; Laurence Klotz
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

Review 10.  Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.

Authors:  A C Buck
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

View more
  4 in total

1.  Safety and toxicity of saw palmetto in the CAMUS trial.

Authors:  Andrew L Avins; Jeannette Y Lee; Catherine M Meyers; Michael J Barry
Journal:  J Urol       Date:  2012-10-09       Impact factor: 7.450

2.  A detailed safety assessment of a saw palmetto extract.

Authors:  Andrew L Avins; Stephen Bent; Suzanne Staccone; Evelyn Badua; Amy Padula; Harley Goldberg; John Neuhaus; Esther Hudes; Katusto Shinohara; Christopher Kane
Journal:  Complement Ther Med       Date:  2008-02-20       Impact factor: 2.446

3.  Stromal growth and epithelial cell proliferation in ventral prostates of liver X receptor knockout mice.

Authors:  Hyun-Jin Kim; Leif C Andersson; Didier Bouton; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

4.  Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments.

Authors:  Nicola Macchione; Paolo Bernardini; Igor Piacentini; Barbara Mangiarotti; Alberto Del Nero
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2019
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.